How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Idelalisib for treating refractory follicular lymphoma

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about idelalisib

Marketing authorisation indication

Idelalisib (Zydelig, Gilead) has a marketing authorisation 'as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment'.

Dosage in the marketing authorisation

Idelalisib is administered orally at a dose of 150 mg, twice daily. Treatment is continued until disease progression or unacceptable toxicity.

Price

The list price for idelalisib is £3,114.75 per pack of 60 150 mg film-coated tablets (excluding VAT, company submission).

The company has a commercial arrangement for idelalisib, which would apply if the technology had been recommended.